Alza

Executive Summary

Unveils two new oral mucosal drug delivery systems, MOTS mucosal oral therapeutic system) for localized delivery and MOSTS system for systemic therapy. Both systems, which are in development, are based on the drug delivery firm's proprietary OROS osmotic pump oral drug delivery system, Alza Co-Chairman and CEO Martin Gerstel told an Alex. Brown health care conference in Baltimore May 8. MOTS/MOSTS overcome disadvantages of previously tried mucosal delivery methods, including lack of "system control" (dosage dumping), short duration of activity, and discomfort or inconvenience, Gerstel said.